| Document |
Document Title |
|
WO/2021/255257A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/239862A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/231737A1 |
The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and p...
|
|
WO/2021/218896A1 |
The present disclosure relates to an ecteinascidin derivative, a preparation method therefor and a medical use thereof, in particular, to a compound represented by general formula (I), a medical use thereof and a preparation method there...
|
|
WO/2021/211922A1 |
The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I) as well as methods of their use and preparation, are also described.
|
|
WO/2021/197295A1 |
The present disclosure relates to a crystalline form of a macrocyclic indole derivative and a preparation method therefor. In particular, the present disclosure relates to a crystalline form of a compound of formula (I) and a preparation...
|
|
WO/2021/165370A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/160617A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating preventing or curing HBV infection and...
|
|
WO/2021/126316A1 |
The present application discloses compounds of Formula (I). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of Mcl-1 proteins and are useful in treating diseases and conditions characterized by ...
|
|
WO/2021/108254A1 |
The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
|
|
WO/2021/099580A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/099579A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/061898A1 |
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for trea...
|
|
WO/2021/032591A1 |
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in...
|
|
WO/2021/032588A1 |
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds ...
|
|
WO/2021/002473A1 |
The invention addresses the problem of providing a compound having Nrf2-activation action. The invention is the compound represented by general formula (I), a salt thereof, or a solvate thereof. General formula (I): In the formula: R1a a...
|
|
WO/2020/254471A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2020/234483A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2020/221272A1 |
The present disclosure relates to an indole macrocyclic derivative, a preparation method therefor and use thereof in medicine. Specifically, the present disclosure relates to an indole macrocyclic derivative represented by general formul...
|
|
WO/2020/206080A1 |
Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.
|
|
WO/2020/185606A1 |
Disclosed are macrocyclic compounds of formula (I) comprising a 2-carboxy indole ring. Such compounds, and their pharmaceutically acceptable salts, are useful as Mcl-1 (myeloid cell leukemia-1) inhibitors. The compounds may be used in tr...
|
|
WO/2020/167984A1 |
Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compoun...
|
|
WO/2020/151738A1 |
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth in the specification. Also provided c...
|
|
WO/2020/147802A1 |
Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are a...
|
|
WO/2020/138015A1 |
The present invention provides: a novel compound that is useful for treating or preventing infections associated with viruses belonging to the subfamily Pneumovirinae, including respiratory syncytial virus (RSV), and that has an anti-RSV...
|
|
WO/2020/103864A1 |
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, Ⓐ, Ⓑ, Ⓒ are as defined as set forth in the specification. Disclosed is compound of formula I f...
|
|
WO/2020/105068A1 |
The present invention relates to an improved and industrially viable process for the preparation of Trabectedin. The present invention also relates to an improved and industrially viable process for the preparation of Trabectedin Interme...
|
|
WO/2020/097577A1 |
The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
|
|
WO/2020/090636A1 |
Provided are: a compound having excellent semiconductor characteristics; a method for producing the compound; an intermediate of the compound; a method for producing the intermediate; and an organic semiconductor material and an organic ...
|
|
WO/2020/063792A1 |
The present invention relates to an indole macrocyclic derivative, a preparation method therefor and an application thereof in medicine. Specifically, the present invention relates to an indole macrocyclic derivative represented by gener...
|
|
WO/2020/050546A1 |
The present invention provides a compound represented by formula 1, an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode, and an ...
|
|
WO/2020/041169A2 |
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as...
|
|
WO/2020/030781A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2020/023560A1 |
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also de...
|
|
WO/2020/016434A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2019/161078A1 |
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...
|
|
WO/2019/126730A1 |
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are d...
|
|
WO/2019/114704A1 |
The present invention provides a preparation method for a natural product Trabectedin. Specifically, the present invention provides a preparation method for Et-743. In the method, tyrosine is used as an initial substrate, and after 26 st...
|
|
WO/2019/097544A1 |
The invention provides a compound for specific detection of SLNPV. Further, the invention provides a probe for specific detection of SLNPV. The probe comprises of a substrate embedded with the compound. The invention also provides a kit ...
|
|
WO/2019/079357A1 |
TNIK inhibitors, conjugates thereof, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in treating of cancer by modulating T...
|
|
WO/2019/053617A1 |
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormµLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt ...
|
|
WO/2019/035927A1 |
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acce...
|
|
WO/2019/035914A1 |
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acce...
|
|
WO/2019/035911A1 |
The present disclosure provides for compounds of formula (I), wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acc...
|
|
WO/2019/035899A1 |
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acce...
|
|
WO/2019/024809A1 |
A bicyclic compound acting as a RORγ inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compoun...
|
|
WO/2019/007793A1 |
The invention relates to the technical field of herbicides and/or plant growth regulators. Specifically, the invention relates to novel isothiazolo-based bicycles, and compositions comprising said novel isothiazolo-based bicycles. Furthe...
|
|
WO/2018/197663A1 |
A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
|
|
WO/2018/178226A1 |
Disclosed are Mcl-1 inhibitors, pharmaceutical compositions comprising the same and methods of using the same.
|
|
WO/2018/153326A1 |
The present invention relates to a sulfonyl hydrazine compound and a use thereof as a medicament for use in treating hepatitis B. Specifically, the present invention discloses a compound which may act as an HBV inhibitor and which has th...
|
